Innovent Biologics, Inc.（1801.HK）股價、財務與研究

歷史價格可能經過調整並有所延遲。

公司概況

Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.

產業: Biotechnology
部門: Healthcare
總部: CN
執行長: De-Chao Yu
上市以來: 2018年10月31日
僱員: 7,502

市場位置

52週區間

目前HK$99.50，

HK$69.55HK$109.1

開盤價: HK$99.50
前收盤價: HK$102.4
成交量: 1083.3萬; 0.78× 平均值
平均成交量: 1390.93萬; 日均成交量
市值: 1732.22億 HKD
貝塔: 0.23; 市場參考 1
50天平均值: HK$87.78; 高於平均水平+13.35%
200天平均值: HK$85.9055; 高於平均水平+15.82%

財務數據

財務快照

估值與收益率

本益比（TTM）: 171.32×
股價淨值比（TTM）: 7.54×
股價營收比（TTM）: 11.39×
股息率: 0.00%

獲利能力和效率

毛利率: 76.42%
營業利益率: 5.63%
淨利潤率: 6.24%

財務健康

負債權益比: 0.15×

財務報表

利潤率趨勢

獲利能力占已公布營收的百分比。

毛利率營業利益率淨利潤率

損益趨勢

營收

130.42億 HKD+38.42%

營業利益

7.34億 HKD+14.89億 HKD

淨利

8.14億 HKD+9.08億 HKD

項目（HKD）	2025會計年度	2024會計年度	2023會計年度	2022會計年度	2021會計年度
營收	130.42億 HKD	94.22億 HKD	62.06億 HKD	45.56億 HKD	42.7億 HKD
銷貨成本	30.44億 HKD	15.1億 HKD	18.07億 HKD	9.31億 HKD	5.73億 HKD
毛利	99.98億 HKD	79.12億 HKD	43.99億 HKD	36.25億 HKD	36.97億 HKD
研究與開發	26.24億 HKD	26.81億 HKD	22.28億 HKD	28.71億 HKD	24.78億 HKD
銷售、一般及管理費用	66.4億 HKD	50.85億 HKD	38.51億 HKD	34.26億 HKD	36.12億 HKD
營業費用	92.64億 HKD	76.54億 HKD	60.79億 HKD	62.07億 HKD	57.49億 HKD
利息收入	4.27億 HKD	4.23億 HKD	4.53億 HKD	1.9億 HKD	1.52億 HKD
利息支出	7753.79萬 HKD	6764.7萬 HKD	9862.4萬 HKD	1.02億 HKD	6246.4萬 HKD
折舊和攤銷	5.77億 HKD	2.76億 HKD	3.85億 HKD	3.19億 HKD	2.05億 HKD
營業利益	7.34億 HKD	−7.56億 HKD	−16.79億 HKD	−31.23億 HKD	−27.03億 HKD
淨利	8.14億 HKD	−9463.1萬 HKD	−10.28億 HKD	−21.79億 HKD	−27.29億 HKD